monovalent influenza subvirion vaccine H7N7

Monovalent influenza subvirion vaccine H7N7 is an inactivated vaccine designed to provide active immunity against the H7N7 subtype of the Influenza A virus. Developed primarily as part of a pandemic preparedness effort following the 2003 outbreak of highly pathogenic avian influenza (HPAI) H7N7 in the Netherlands, the vaccine was advanced by Sanofi Pasteur in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). The subvirion, or 'split-virus', manufacturing process involves treating the influenza virus with detergents to disrupt the viral envelope, resulting in a product that is less reactogenic than whole-virus vaccines while retaining the immunogenic properties of viral surface glycoproteins. Its primary mechanism of action is the induction of neutralizing antibodies against the viral hemagglutinin (HA) protein, which prevents the virus from binding to and entering host respiratory epithelial cells. While clinical trials established its safety and immunogenicity, the vaccine remains an investigational candidate intended for emergency use in the event of an H7N7 influenza pandemic.

Other names

Inactivated monovalent influenza A (H7N7) virus vaccineA/Netherlands/219/2003 (H7N7) subvirion vaccineH7N7 influenza vaccineH-7N7 influenza vaccineH 7N7 influenza vaccineH7N7 subvirion vaccineH-7N7 subvirion vaccineH 7N7 subvirion vaccine